Login to Your Account



Pozen's Stock Crushed On Trexima Approvable Letter

By Aaron Lorenzo


Monday, June 12, 2006
The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription